Q-omics provides the consensus-scored DNALI1 profile across patient tissues and cancer cell-line models. DNALI1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DNALI1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, DNALI1 RNA expression shows 17,897 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, KICH, and KIRP as cancer lineages where DNALI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNALI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNALI1 survival associations across molecular data types. DNALI1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNALI1 RNA expression–survival associations across cancer types. High DNALI1 expression shows favorable associations in ACC, KIRC, UVM, HNSC, LUAD and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DNALI1 RNA expression.
This table summarizes DNALI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNALI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNALI1 shows lower tumor expression in KICH, THCA, BLCA, LUSC and LUAD and higher tumor expression in CHOL. The KICH box plot shows higher DNALI1 RNA expression in normal versus tumor tissue (log2 FC = −3.473, t-test p < 0.001).
This table shows molecular features associated with DNALI1 in patient tissues and cancer cell lines. In patient samples, DNALI1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DNALI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
